Our turnkey facility solutions for commercial cell and gene therapy manufacturing deliver fully integrated, risk-based capital project delivery for advanced therapy medicinal product (ATMP) manufacturers scaling from late-stage clinical campaigns into full commercial production. This end-to-end engineering offering unifies process equipment integration, cleanroom architecture, critical utility build, automation infrastructure and regulatory compliance design under a single project delivery framework, tailored to the unique constraints of autologous, allogeneic and viral vector manufacturing workflows. We develop facility master planning aligned with user requirement specifications, embedding closed automated processing systems, biocontainment controls and segregation strategies from the conceptual design phase, to avoid costly post-construction retrofits while meeting the rigorous cGMP, ISO 14644 and global ATMP regulatory expectations for commercial-scale cell and gene therapy production.
The complete turnkey scope covers front-end conceptual design, site master planning, cleanroom zoning and flow design, HVAC and pressure cascade engineering, purified water, clean compressed gas, process drain and waste handling system construction, alongside integration of bioreactors, cell processing instruments, isolators and automated material transfer systems. CFD airflow modelling, environmental risk mapping and utility load analysis underpin all design decisions to stabilize critical process parameters across classified manufacturing, material staging, quarantine, decontamination and quality control laboratories. Our deliverable package includes full construction documentation, P&ID drawings, equipment interface schematics, commissioning and qualification protocols, FAT/SAT management and validation master planning, engineered in strict alignment with EU GMP Annex 1, FDA cGMP and regional regulatory codes governing cell and gene therapy commercial manufacturing.
Consolidated turnkey project delivery eliminates interface gaps between multiple separate engineering vendors, reducing schedule slippage, contractual ambiguity and technical conflicts common in fragmented facility builds. Purpose-designed zoning and airflow architecture minimize manual intervention within high-value aseptic processing zones, lowering cross-contamination risk and reducing the validation burden for complex cell and viral vector workflows. Modular facility design enables staged capacity expansion, allowing operators to incrementally add production suites without disrupting existing commercial batch operations. Built-in continuous environmental monitoring and digital audit trail systems support full batch traceability, shortening regulatory inspection preparation cycles and strengthening readiness for global marketing authorization audits.
This turnkey facility offering serves cell and gene therapy CDMOs, biotech sponsors and pharmaceutical enterprises commercializing CAR-T, NK cell therapies, stem cell products, AAV and lentiviral vector materials. Beyond design and construction execution, our service extends to construction supervision, multi-system commissioning, installation and performance qualification, regulatory gap assessment and long-term facility operational advisory. Our integrated turnkey model empowers advanced therapy developers to compress overall project timelines, optimize capital expenditure, establish resilient, inspection-grade manufacturing infrastructure and accelerate global commercial launch of life-changing cell and gene therapy products.
